Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma
Author:
- 3 July 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (1) , 183-190
Abstract
Patients with refractory/early relapsed aggressive lymphomas belong to the most difficult-to-treat patients with hematological neoplasia. The prognosis of such patients is poor and novel treatment approches are urgently needed. Autologous chimeric antigen receptor T-cell therapy is a promising new therapy option that is approved after the failure of two lines of chemotherapy. Recently, the results of three different CART studies (ZUMA-7, TRANSFORM, and BELINDA) were published. Two of them were positive and one was negative, which created a mix of disappointment, confusion, and irritation. In this article, we are analyzing the data of all three trials and shed light on the differences between the studies which may facilitate an easier understanding of the results and relevance of CART in aggressive large B-cell lymphoma.Keywords
This publication has 23 references indexed in Scilit:
- 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T CellsFrontiers in Immunology, 2020
- Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphomaBlood Advances, 2020
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaBlood Advances, 2020
- Treatment of Aggressive B Cell Lymphomas: Updates in 2019Current Hematologic Malignancy Reports, 2020
- TRUCKS, the fourth‐generation CAR T cells: Current developments and clinical translationAdvances in Cell and Gene Therapy, 2020
- How I manage patients with relapsed/refractory diffuse large B cell lymphomaBritish Journal of Haematology, 2018
- Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphomaTherapeutics and Clinical Risk Management, 2018
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy2015